David Linemeyer

Title: The Innovative Contributions of David Linemeyer

Introduction

David Linemeyer is a notable inventor based in Guilford, CT (US). He has made significant contributions to the field of biotechnology, particularly in the study of galanin receptors. With a total of 5 patents to his name, Linemeyer has demonstrated a commitment to advancing scientific knowledge and innovation.

Latest Patents

One of Linemeyer's latest patents focuses on the "Uses of galanin GALR2 receptors." This invention provides isolated nucleic acids encoding mammalian galanin receptors, isolated galanin receptor proteins, vectors comprising isolated nucleic acid encoding a mammalian galanin receptor, and cells comprising such vectors. Additionally, it includes antibodies directed to a mammalian galanin receptor, nucleic acid probes useful for detecting nucleic acid encoding a mammalian galanin receptor, and antisense oligonucleotides complementary to unique sequences of nucleic acid encoding a mammalian galanin receptor. The patent also covers nonhuman transgenic animals that express DNA encoding a normal or a mutant mammalian galanin receptor, as well as methods of determining the binding of compounds to mammalian galanin receptors.

Another significant patent by Linemeyer is the "Method of preparing GALR2 receptors composition." Similar to his previous patent, this invention provides isolated nucleic acids encoding mammalian galanin receptors, isolated galanin receptor proteins, and vectors comprising isolated nucleic acid encoding a mammalian galanin receptor. It also includes cells comprising such vectors, antibodies directed to a mammalian galanin receptor, nucleic acid probes, and antisense oligonucleotides. Furthermore, it addresses nonhuman transgenic animals that express DNA encoding a normal or a mutant mammalian galanin receptor, along with methods for determining the binding of compounds to mammalian galanin receptors.

Career Highlights

Throughout his career, David Linemeyer has worked with prominent companies in the pharmaceutical industry, including Synaptic Pharmaceutical Corporation and H. Lundbeck A/S. His work has significantly impacted the understanding of galanin receptors and their potential therapeutic applications.

Collaborations

Linemeier has collaborated with notable colleagues such as Kelli E. Smith and Richard L. Weinshank. These collaborations have further enriched his research and contributed to the advancement of knowledge in his field.

Conclusion

David Linemeyer